Protalix BioTherapeutics Files Q1 2025 10-Q
Ticker: PLX · Form: 10-Q · Filed: May 9, 2025 · CIK: 1006281
| Field | Detail |
|---|---|
| Company | Protalix Biotherapeutics, Inc. (PLX) |
| Form Type | 10-Q |
| Filed Date | May 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
**Protalix BioTherapeutics Q1 2025 10-Q filed. Financials updated.**
AI Summary
Protalix BioTherapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operational updates. Key financial figures such as retained earnings and additional paid-in capital are reported for various periods, including March 31, 2025, December 31, 2024, and March 31, 2024.
Why It Matters
This filing provides investors with an updated view of Protalix BioTherapeutics' financial health and performance in the first quarter of 2025, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Protalix BioTherapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-09 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Protalix BioTherapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of the reporting period
- 20250509 (date) — Filing date
FAQ
What is the primary business of Protalix BioTherapeutics, Inc.?
Protalix BioTherapeutics, Inc. is in the business of biological products, specifically excluding diagnostic substances, as indicated by its SIC code [2836].
What is the fiscal year end for Protalix BioTherapeutics?
The fiscal year end for Protalix BioTherapeutics is December 31st.
What was the previous name of Protalix BioTherapeutics?
Protalix BioTherapeutics was formerly known as ORTHODONTIX INC, with a name change date of 19980422, and prior to that, EMBASSY ACQUISITION CORP, with a name change date of 19960124.
What specific financial statement items are listed for the reporting period?
The filing lists us-gaap:RetainedEarningsMember and us-gaap:AdditionalPaidInCapitalMember for various dates, including 2025-03-31.
What is the SEC file number for Protalix BioTherapeutics?
The SEC file number for Protalix BioTherapeutics is 001-33357.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding Protalix BioTherapeutics, Inc. (PLX).